Drug Trial Radar · NCT05751850
HR070803 in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Advanced Pancreatic Cancer
Last checked: Nov 19, 2026Latest source record: May 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
778
Planned (sponsor's estimate)
Start
Jun 13, 2023
Primary completion
Dec 30, 2024
Study completion Dec 30, 2025
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 2, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to look at the efficacy and safety of HR070803 in combination with 5 fluorouracil/leucovorin (5FU/LV) plus oxaliplatin compared to nab-paclitaxel + gemcitabine treatment in improving the overall survival of patients not previously treated for metastatic pancreatic cancer.
Conditions
- First-line Treatment of Advanced Pancreatic Cancer
Interventions
HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinateDrug
HR070803 in combination with oxaliplatin, 5-fluorouracil, calcium folinate
nab-paclitaxel; gemcitabineDrug
nab-paclitaxel in combination with gemcitabine
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survival (OS)Time frame: From study start until 399 OS events have occurred (approximately 15 months after last patient enrollment)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.